Showing papers by "William N. Washburn published in 2013"
TL;DR: Current evidence suggests that SGLT2 inhibitors have similar efficacy in terms of glycemic control and also demonstrate benefits beyond glycemic reductions, including reductions in body weight and modest reductions in blood pressure.
Abstract: Introduction: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a novel class of agents for the treatment of type 2 diabetes mellitus (T2DM). By inhibiting SGLT2, they prevent renal glucose reabsorption, resulting in glucosuria. Areas covered: The rationale for development of SGLT2 inhibitors is reviewed, with particular focus on the nine SGLT2 inhibitors currently in development. The authors compare the potency and SGLT2 selectivity of the agents, as well as the results from both animal and clinical studies, considering the potential implications they may have for clinical use. Expert opinion: Current evidence suggests that SGLT2 inhibitors have similar efficacy in terms of glycemic control and also demonstrate benefits beyond glycemic reductions, including reductions in body weight and modest reductions in blood pressure. Additionally, they appear to preserve beta-cell function and improve insulin sensitivity. Their mechanism of action allows for combination of SGLT2 inhibitors with other antidiabe...
73 citations
TL;DR: Theobroma cacao was detected in the ceramic assemblage at the 8th century Site 13, Alkali Ridge, southeastern Utah as mentioned in this paper, and the presence of this Mesoamerican beverage during the Pueblo I period is the earliest reported use of cacao in the northern American Southwest.
18 citations
Patent•
03 Sep 2013TL;DR: In this article, the authors defined compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds, which are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.
Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are melanin concentrating hormone receptor-1 (MCHR1) antagonists which may be used as medicaments.
1 citations